Reduced cell surface expression of CCR5 in CCR5Delta 32 heterozygotes is mediated by gene dosage, rather than by receptor sequestration.
about
Rab26 modulates the cell surface transport of α2-adrenergic receptors from the GolgiRole for CCR5Delta32 protein in resistance to R5, R5X4, and X4 human immunodeficiency virus type 1 in primary CD4+ cellsLack of association between the chemokine receptor 5 polymorphism CCR5delta32 in rheumatoid arthritis and juvenile idiopathic arthritis.Effects of the Chemokine Receptor 5 (CCR5)-Delta32 Mutation on Hepatitis C Virus-Specific Immune Responses and Liver Tissue Pathology in HCV Infected Patients.Rab8 interacts with distinct motifs in alpha2B- and beta2-adrenergic receptors and differentially modulates their transport.Combined effect of CCR5-Delta32 heterozygosity and the CCR5 promoter polymorphism -2459 A/G on CCR5 expression and resistance to human immunodeficiency virus type 1 transmissionAssociation of the CCR5 gene with juvenile idiopathic arthritis.Frequency of CCR5Δ32 allele in healthy Bosniak populationPersistent resistance to HIV-1 infection in CD4 T cells from exposed uninfected Vietnamese individuals is mediated by entry and post-entry blocks.Increased frequency of circulating CCR5+ CD4+ T cells in human immunodeficiency virus type 2 infectionDistinct mechanisms of agonist-induced endocytosis for human chemokine receptors CCR5 and CXCR4The Effects of the Recombinant CCR5 T4 Lysozyme Fusion Protein on HIV-1 Infection.Regulation of G protein-coupled receptor export trafficking.Anterograde trafficking of nascent α(2B)-adrenergic receptor: structural basis, roles of small GTPasesGene therapy progress and prospects: novel gene therapy approaches for AIDS.CCR5Delta32 59537-G/A promoter polymorphism is associated with low translational efficiency and the loss of CCR5Delta32 protective effectsRegulation of anterograde transport of alpha2-adrenergic receptors by the N termini at multiple intracellular compartments.Resistance to human immunodeficiency virus type 1 (HIV-1) generated by lentivirus vector-mediated delivery of the CCR5{Delta}32 gene despite detectable expression of the HIV-1 co-receptors.Increased expression of intrinsic antiviral genes in HLA-B*57-positive individualsCCR5 deletion protects against inflammation-associated mortality in dialysis patients.Coregulation of HIV-1 dependency factors in individuals heterozygous to the CCR5-delta32 deletion.HIV-1 Nef down-modulates C-C and C-X-C chemokine receptors via ubiquitin and ubiquitin-independent mechanismPharmacological modulation of chemokine receptor function.On the mechanism and significance of ligand-induced internalization of human neutrophil chemokine receptors CXCR1 and CXCR2.CCR5Delta32 protein expression and stability are critical for resistance to human immunodeficiency virus type 1 in vivoCXCR4/CCR5 down-modulation and chemotaxis are regulated by the proteasome pathway.CCR5-Delta32 mutation is strongly associated with primary sclerosing cholangitis.Association of the CC chemokine receptor 5 (CCR5) polymorphisms with preeclampsia in Turkish women.Rescue of HIV-1 Receptor Function through Cooperation between Different Forms of the CCR5 Chemokine Receptor
P2860
Q24302003-49AAE7ED-3186-41CB-9B03-0AEFE1A1BFC6Q24608200-7954B730-CEAF-4004-94EE-74F2821DA704Q33287486-CA543934-1DA7-4A7C-BAB5-68B41D275AFDQ33912466-FD3E1CDB-3833-4E57-9BB7-C4B67D2F740BQ33924469-44982172-6737-49A3-A541-DC79F73F415EQ33987424-5F20A0F6-C82B-4A90-A4F8-C2E5185B5CCFQ34282309-272704EB-B39E-454A-A093-9F4836ACAAC7Q35099993-0D509143-77FD-4498-8D85-A2D6C26C90DAQ35131130-3C01F649-DFE6-4F06-BE6E-6EB60B59EFD8Q35185919-45E9F4E4-2A86-434A-9068-C9B5953CAE66Q35670389-02A2355E-597C-4E05-BB0E-007DBFD7F7CFQ35685881-3D3553EE-4B31-4A6E-A1A4-8E0905FC0DAEQ35827970-ABBCE3BB-9BCE-4518-9449-A78039F8BD93Q35875489-432A85ED-FD2B-40D0-9BB6-730B80FFA4BAQ36036704-4CBBD5DE-3A00-4D5D-9216-EFDFC4246AD4Q36483857-82941B3A-D63C-4BE4-BC01-3F34CE357565Q37111559-54CBDB79-D32E-4740-B818-A341502736C0Q37185404-CE0146C5-EA8A-4DF3-94B8-B7F0C2EA5A5AQ37238299-C8159D36-B16E-4B95-9978-8D21C9C717F6Q37259261-38B3F62F-59A1-4E4A-9B4D-E77799BB2458Q37326697-2577260E-B3B7-4C93-9FF4-E03DE47DF19DQ37529530-CE3420FF-E204-4475-A4A2-2A7A89D0592FQ37893687-E88D8C69-483A-4D82-A52B-31DECB0EDD89Q40577138-E5CFC5D7-9C48-431D-8D5C-DCCB6230EB6CQ41860559-69DC615F-C7E2-4495-B4F3-47552123C7D9Q43904707-0E618B43-D1A4-450F-9C32-A34516617A0DQ47293732-C7C795F6-65A4-4920-85E9-F3FFD5E9F7D7Q54325199-A862F9FD-AE94-48B3-8EDA-43DF622D19F3Q57372060-27BE584E-2E43-444A-AB8A-FE85EF2D71F8
P2860
Reduced cell surface expression of CCR5 in CCR5Delta 32 heterozygotes is mediated by gene dosage, rather than by receptor sequestration.
description
2001 nî lūn-bûn
@nan
2001年の論文
@ja
2001年論文
@yue
2001年論文
@zh-hant
2001年論文
@zh-hk
2001年論文
@zh-mo
2001年論文
@zh-tw
2001年论文
@wuu
2001年论文
@zh
2001年论文
@zh-cn
name
Reduced cell surface expressio ...... han by receptor sequestration.
@en
Reduced cell surface expressio ...... han by receptor sequestration.
@nl
type
label
Reduced cell surface expressio ...... han by receptor sequestration.
@en
Reduced cell surface expressio ...... han by receptor sequestration.
@nl
prefLabel
Reduced cell surface expressio ...... han by receptor sequestration.
@en
Reduced cell surface expressio ...... han by receptor sequestration.
@nl
P2093
P2860
P356
P1476
Reduced cell surface expressio ...... han by receptor sequestration.
@en
P2093
Ana Petrovic
Donald I Van Ryk
Drew Weissman
Massimo Locati
Philip M Murphy
Sundararajan Venkatesan
P2860
P304
P356
10.1074/JBC.M108321200
P407
P577
2001-10-16T00:00:00Z